EXTENDED REPORTS

Duration of preclinical rheumatoid arthritis-related autoantibody positivity increases in subjects with older age at time of disease diagnosis

D S Majka¹, K D Deane², L A Parrish², A A Lazar³, A E Barón³, C W Walker⁴, M V Rubertone⁵, W R Gilliland⁴, J M Norris³, V M Holers²

¹ Division of Rheumatology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA
² Division of Rheumatology, University of Colorado at Denver and Health Sciences Center, Denver, Colorado, USA
³ Department of Preventive Medicine and Biometrics, University of Colorado at Denver and Health Sciences Center, Denver, Colorado, USA
⁴ Department of Medicine, Rheumatology Section, Walter Reed Army Medical Center, Washington DC, USA
⁵ US Army Center for Health Promotion and Preventive Medicine, Washington, DC, USA

Dr V M Holers, Division of Rheumatology, University of Colorado at Denver and Health Sciences Center, Barbara Davis Center, 1775 North Ursula Street, B-115, Aurora, Colorado 80045, USA; Michael.Holers{at}uchsc.edu

Objectives: To investigate factors that may influence the prevalence and timing of appearance of rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies during the preclinical phase of rheumatoid arthritis (RA) development.

Methods: 243 serial prediagnosis serum samples from 83 subjects with RA were examined for the presence of RF and anti-CCP antibodies.

Results: Of the 83 cases, 47 (57%) and 51 (61%) subjects had at least one prediagnosis sample positive for RF or anti-CCP, respectively. Gender and race were not significantly associated with the prevalence or timing of preclinical antibody appearance. Preclinical anti-CCP positivity was strongly associated with the development of erosive RA (odds ratio = 4.64; 95% confidence interval 1.71 to 12.63; p<0.01), but RF was not (p = 0.60). Additionally, as age at the time of diagnosis of RA increased the duration of prediagnosis antibody positivity for RF and anti-CCP increased, with the longest duration of preclinical antibody positivity seen in patients diagnosed with RA over the age of 40. In no subjects did symptom onset precede the appearance of RF or anti-CCP antibodies.

Conclusions: The period of time that RF and anti-CCP are present before diagnosis lengthens as the age at the time of diagnosis of RA increases. This finding suggests that factors such as genetic risk or environmental exposure influencing the temporal relationship between the development of RA-related autoantibodies and clinically apparent disease onset may differ with age.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• El-GABALAWY, H. S., ROBINSON, D. B., HART, D., ELIAS, B., MARKLAND, J., PESCHKEN, C. A., SMOLIK, I., MONTES-ALDANA, G., SCHROEDER, M., FRITZLER, M. J., CHEANG, M., OEN, K. (2009). Immunogenetic Risks of Anti-Cyclical Citrullinated Peptide Antibodies in a North American Native Population with Rheumatoid Arthritis and Their First-degree Relatives. The Journal of Rheumatology 36: 1130-1135 [Abstract] [Full Text]  
• FESER, M., DERBER, L. A., DEANE, K. D., LEZOTTE, D. C., WEISMAN, M. H., BUCKNER, J. H., MIKULS, T., O'DELL, J., GREGERSEN, P. K., HOLERS, V. M., NORRIS, J. M. (2009). Plasma 25,OH Vitamin D Concentrations Are Not Associated with Rheumatoid Arthritis (RA)-related Autoantibodies in Individuals at Elevated Risk for RA. The Journal of Rheumatology 36: 943-946 [Abstract] [Full Text]  
• MENARD, H. A. (2009). Anti-Cyclic Citrullinated Peptide in Preclinical Rheumatoid Arthritis. Food for Thought. The Journal of Rheumatology 36: 663-664 [Full Text]  
• Bos, W H, Nielen, M M J, Dijkmans, B A C, van Schaardenburg, D (2008). Duration of pre-rheumatoid arthritis anti-cyclic citrullinated peptide positivity is positively associated with age at seroconversion. Ann Rheum Dis 67: 1642-1642 [Full Text]